First data for Lilly's RNA treatment for heart disease point to long-term durability in tiny group of patients
PHILADELPHIA — Eli Lilly’s investigational RNA silencing drug lowered levels of lipoprotein(a) in an early-stage study. Elevated levels of Lp(a) have been associated with a higher risk of heart disease, heart attack and stroke.
In 48 adult participants with elevated Lp(a) levels who did not have heart disease, researchers tested six different doses of a one-time injection of lepodisiran. The doses ranged from 4 mg to 608 mg and included a placebo. At the highest dose, which was given to six people, Lp(a) levels fell below what researchers were able to reliably measure after one month and stayed that low until the nine-month mark. At nearly one year, the participants who received the highest dose had Lp(a) levels that were 94% lower than when they started the trial.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
